16880-11-8

Basic information

• Product Name: 5-Isoxazolecarboxylicacid,3-methoxy-,methylester(8CI,9CI)
• Synonyms: 5-Isoxazolecarboxylicacid,3-methoxy-,methylester(8CI,9CI);5-Isoxazolecarboxylic acid, 3-Methoxy-, Methyl ester;Methyl 3-Methoxyisoxazole-5-carboxylate;3-Methoxy-isoxazole-5-carboxylic acid methyl ester
• CAS NO: 16880-11-8
• Molecular Formula: C₆H₇NO₄
• Molecular Weight: 157.12
• Product Categories: OXAZOLE
• Mol File: 16880-11-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Isoxazolecarboxylicacid,3-methoxy-,methylester(8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoxazolecarboxylicacid,3-methoxy-,methylester(8CI,9CI)(16880-11-8)
• EPA Substance Registry System: 5-Isoxazolecarboxylicacid,3-methoxy-,methylester(8CI,9CI)(16880-11-8)

Safety Data

• Hazardous Substances Data: 16880-11-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 13626-59-0 3-methoxyisoxazole-5-carboxylic acid 
• 10068-07-2 methyl 3-hydroxy-5-isoxazolecarboxylate 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 205115-33-9 2-Benzyl-3-oxo-2,3-dihydro-isoxazole-5-carboxylic acid methyl ester 
• 205115-22-6 3-benzyloxyisoxazole-5-carboxylic acid methyl ester 
• 186581-53-3 diazomethane 

Downstream Products

• 145441-09-4 3-Methoxy-isoxazole-5-carboxylic acid (2,6-dimethyl-phenyl)-amide 
• 13626-59-0 3-methoxyisoxazole-5-carboxylic acid 
• 35166-36-0 3-methoxy-5-hydroxymethylisoxazole 
• 2763-94-2 5-aminomethyl-3-methoxyisoxazole 
• 100241-86-9 3-methoxy-5-(N-methyl-N-benzylaminoethyl)isoxazole 
• 143268-28-4 2-<(3-methoxy-5-isoxazolyl)methyl>-3-imino-8-phenyl-2,3-dihydrobenzopyridazine hydrochloride 
• 143268-27-3 2-<(3-methoxy-5-isoxazolyl)methyl>-3-imino-6-(p-chlorophenyl)-2,3-dihydropyridazine hydrochloride 
• 143268-25-1 2-<(3-methoxy-5-isoxazolyl)methyl>-3-imino-6-phenyl-2,3-dihydropyridazine hydrochloride 

Relevant articles and documents

THAILANSTATIN ANALOGS

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins i

FTO INHIBITORS

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

O-Alkylation of 3-hydroxyisoxazoles predominates under Mitsunobu conditions

Regiochemical control in the functionalization of ambident nucleophiles is of particular interest in organic chemistry. Herein, we demonstrate that O-alkylation of ambident 3-hydroxyisoxazoles, which are heterocyclic bioisosteres of carboxylic acids, predominates under Mitsunobu conditions. In several cases, excellent O-regioselectivity (≥95%) was observed. It is noteworthy that reactions were complete within 15 min at room temperature. Furthermore, the conditions are compatible with a range of alcohols that cover all of the typical protecting groups for the 3-hydroxyisoxazole motif, providing milder, simpler and less hazardous protocols to those commonly followed in the literature.

Practical synthesis of a potent bradykinin B1 antagonist via enantioselective hydrogenation of a pyridyl N-acyl enamide

(Chemical Equation Presented) A practical and efficient synthesis of bradykinin B1 antagonist 1 is described. A convergent strategy was utilized which involved synthesis of three fragments: 3, 6, and 7. Cross coupling of fragments 6 and 7 followed by amidation with 3 enabled efficient synthesis of 1 in 19 steps total, a 35% overall yield from commercially available pyridine 10. The key to the success of the synthesis was the development of a fluorodenitration step to install the fluorine in pyridine 7 and a catalytic enantioselective hydrogenation of N-acyl enamide 9 to set the stereochemistry.

MALONONITRILE COMPOUND AS PESTICIDES

The present invention provides a malononitrile compound represented by the formula (I): wherein any one of X1, X2, X3 and X4 is CR100, wherein R100 is a group represented by the formula: the other three of X1, X2, X3 and X4 each represent nitrogen or CR5, provided that 1 to 3 of X1, X2, X3 and X4 represent nitrogen, and Z represents oxygen, sulfur or NR6, which has pest-controlling activity.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

Evaluation of protecting groups for 3-hydroxyisoxazoles - Short access to 3-alkoxyisoxazole-5-carbaldehydes and 3-hydroxyisoxazole-5-carbaldehyde, the putative toxic metabolite of muscimol

The regioselectivity of the 3-hydroxyisoxazole-5-ester 1 is studied with respect to O- versus N-alkylation. 3-O-Alkyl products 2 are highly favoured with benzyl, benzhydryl, and allyl bromide (≥ 91:9), in contrast to known uses of 5-alkyl-3-hydroxyisoxazoles or when methylation with diazomethane (or methyl iodide) is effected. Methoxymethylation leads to the N-substituted isoxazolinone 3e only. On reduction with DIBAH, the esters 2 afford 3-O-protected 3-hydroxyisoxazole-5-carbaldehydes 4 (75-98%). For removal of the benzyl protecting groups, three variations (HBr/HOAc, H2/ Pd/BaSO4, NBS/AIBN) were found useful with 5-ester, 5-formyl, and 5-hydroxymethyl derivatives. The free 3-hydroxy-5-carbaldehyde 9, the putative toxic metabolite of the GABA agonist muscimol, is prepared accordingly. The O-protected 3-hydroxyisoxazole-5-carbaldehydes 4 constitute versatile intermediates in various routes to analogues of CNS-active amino acids and can now be obtained in a highly efficient manner.

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

Condensation of muscimol or thiomuscimol with aminopyridazines yields GABA-A antagonists

Ten analogs of muscimol and thiomuscimol in which the amino function was delocalized in an amidinic system were prepared by N2 alkylation of 6-aryl-3- aminopyridazines with (chloromethyl)isoxazole or (chloromethyl)isothiazole derivatives. These muscimol a